EC1169 is a targeted tubulysin conjugate that utilizes EC1167 as its linker. This compound shows promise in the treatment of recurrent metastatic, castration-resistant prostate cancer (MCRPC)[1].
Imalumab (BAX69) is a recombinant humanised monoclonal antibody that targets and inhibits MIF (macrophage inhibitory factor), exhibiting anticancer activity. It is applicable for advanced solid tumours such as ovarian cancer and non-small cell lung cancer.